Abstract

GUEVARA-CUELLAR, CÉSAR AUGUSTO. Cost utility of prophylaxis with palivizumab versus no prophylaxis in children with risk of infection of syncitial respiratory virus in Colombia. CES Med. [online]. 2014, vol.28, n.2, pp.203-219. ISSN 0120-8705.

ABSTRACT Objective: To determine the incremental cost utility ratio (ICUR) of prophylaxis with palivizumab in children with risk factors for infection by respiratory syncytial virus (RSV). Material and methods: A decision tree using the perspective of the Colombian health sector was conducted in preterm infants (<35weeks) and children with congenital heart disease (CHD) using local data on costs and effectiveness data for the calculation of quality adjusted life years (QALYs) from randomized clinical trials with a time horizon of their life expectancy. Costs were reported in Colombian pesos ($ ColP) and a discount rate of 3.5 % was applied. The model was evaluated using a Monte Carlo simulation. Results: The costs of palivizumab in the preterm group were $8'944.789 and the group of non palivizumab $1'846.634. The QALY in these groups were 72.28 and 72.17 respectively. The ICUR was $65'528.681/QALY additional. In the group of children with CHD the costs of palivizumab were $15'191.700 and $4'657.187 in no palivizumab group. The QALYs in these groups were 72.16 and 71.94, respectively. The ICUR was $47'884.150/QALY. There is a probability greater than 50 % of being cost-effective with a willingness to pay of $60'000.000. Conclusions: Palivizumab provides a costeffective alternative of prophylaxis against RSV infection

Keywords : Economics; Medical; Cost Efficiency Analysis; Respiratory Syncytial Viruses; Antibodies; monoclonal; Quality-adjusted life years.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )